61-70 of 667 results
Case of the 'x' – collaborations in the metaverse
The explosion of the metaverse into popular consciousness has created a wealth of exciting new commercial opportunities for businesses. However, as discussed in more detail in this Insight, these collaborative projects give rise to a number of unique and important legal considerations. ...
Minimum fines of $10 million – why compliance with the Franchising Code is now more important than ever
In April this year, highly anticipated increases to the financial penalties for contravening the Franchising Code (the Code) came into effect. As a result of these changes, it's essential that business review their franchise agreements to ensure they remain compliant with the Franchising Code. ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...
IP Australia releases new guidance on classifying emerging technology trade marks
IP Australia recently released new guidance on how to classify trade mark goods and services that relate to the emerging technologies of virtual goods, the metaverse, non-fungible tokens (NFTs) and blockchains. We outline how the guidance may be relevant to your business and also provide some practical suggestions for dealing with applications and registrations affected by it. ...
In Touch: Delta's bid rigging on full display; and other developments
The latest in competition and consumer law. ...
InIP: What's happening in intellectual property - August 2023
Your regular wrap-up of some of the world's leading and intriguing IP stories. ...
Australian Government takes its $325 million damages claim to the High Court in Commonwealth v Sanofi
The Full Court has confirmed that the Australian Government is not entitled to any damages from Sanofi and Bristol-Myers Squibb. In this Insight, we examine the appeal decision and consider its implications for patent infringement proceedings relating to pharmaceutical products. ...
ESG contract clauses — drafting tips to reduce your exposure to disputes and complaints
Interest in environmental, social and governance (ESG) is continuing to grow at a rapid pace, including ESG-related goods and services. ...
Why intellectual property should be a key component of your ESG agenda
In this Insight, we unpack a number of IP considerations that should be integrated into a comprehensive ESG approach. ...